Companies › UniQure Biopharma
4 active drug programs in 5 registered trials: 5 Phase 1; Neurology, Metabolic and endocrine; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AAV9-hSyn1-miGRIK2 (AMT-260) AAV9 gene therapy delivering miRNA to silence GRIK2 and suppress GluK2-containing kainate | GRIK2 | Phase 1 | Mesial Temporal Lobe Epilepsy | Nov 2026 |
| AMT-191 AAV5-based gene therapy delivering human α-galactosidase A | GLA | Phase 1 | Fabry Disease | Dec 2027 |
| AMT-130 rAAV5-miHTT gene therapy - delivers microRNA targeting mutant huntingtin (HTT) mRNA | HTT | Phase 1 | Huntington Disease; Huntington's Disease | Mar 2029 |
| AMT-162 Self-complementary AAV serotype rh10 vector delivering miRNA targeting SOD1 | SOD1 | Phase 1 | Amyotrophic Lateral Sclerosis | Jun 2031 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06063850 | AAV9-hSyn1-miGRIK2 (AMT-260) | Phase 1 | Mesial Temporal Lobe Epilepsy | Neurology | Nov 2026 |
| NCT06270316 | AMT-191 | Phase 1 | Fabry Disease | Metabolic and endocrine | Dec 2027 |
| NCT05243017 | AMT-130 | Phase 1 | Huntington Disease | Neurology | Mar 2029 |
| NCT04120493 | AMT-130 | Phase 1 | Huntington's Disease | Neurology | Jun 2029 |
| NCT06100276 | AMT-162 | Phase 1 | Amyotrophic Lateral Sclerosis | Neurology | Jun 2031 |
Roche Chiesi Farmaceutici Amicus Therapeutics Takeda 4D Molecular Therapeutics Alnylam Pharmaceuticals Novartis ExoRNA Bioscience Biogen Regeneron Pharmaceuticals
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.